ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.287,97
0,10%
S&P 500
5.230,07
0,17%
US Dollar vs BRL
5,1334
-0,43%
Bitcoin
61.599,24
-2,07%
Brent Oil
82,815
-0,47%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) Notícias

GNPX

Genprex (GNPX)

Genprex Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GNPX
DataHoraFonteTítuloCódigoCompanhia
14/05/202409:31PR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
13/05/202409:31PR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
09/05/202409:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
08/05/202419:08PR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
01/05/202409:31PR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
09/04/202409:31PR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
03/04/202409:31PR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/04/202409:31PR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
22/03/202417:10PR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
19/03/202414:24PR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
12/03/202410:01PR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
06/03/202410:30PR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
21/02/202418:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
14/02/202416:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNPXGenprex Inc
07/02/202410:15PR Newswire (US)Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsNASDAQ:GNPXGenprex Inc
06/02/202409:30PR Newswire (US)Genprex to Present at Upcoming BIO CEO & Investor ConferenceNASDAQ:GNPXGenprex Inc
05/02/202409:30PR Newswire (US)Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
31/01/202410:42PR Newswire (US)Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024NASDAQ:GNPXGenprex Inc
05/01/202409:00PR Newswire (US)Genprex Provides Business Update and Outlook for 2024NASDAQ:GNPXGenprex Inc
13/12/202318:50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
14/11/202313:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
03/11/202317:19Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GNPXGenprex Inc
03/11/202317:16Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:GNPXGenprex Inc
01/11/202308:30PR Newswire (US)Genprex to Present at BIO-Europe 2023 ConferenceNASDAQ:GNPXGenprex Inc
23/10/202318:01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:GNPXGenprex Inc
20/10/202308:30PR Newswire (US)Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"NASDAQ:GNPXGenprex Inc
04/10/202313:00PR Newswire (US)Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:GNPXGenprex Inc
21/09/202309:30GlobeNewswire Inc.Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCNASDAQ:GNPXGenprex Inc
20/09/202309:45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:GNPXGenprex Inc
07/09/202308:30PR Newswire (US)Genprex to Present at Upcoming September Investor ConferenceNASDAQ:GNPXGenprex Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GNPX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
RNEW4
RENOVA PN
BOV
ENJU3
Enjoei ON
BOV
IRBR3
IRB BRASIL ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
TECN3
TECHNOS ON
BOV
RCSL4
RECRUSUL PN
BOV
FESA4
FERBASA PN
BOV
POSI3
POSITIVO TEC ON
BOV
SAPR4
SANEPAR PN
BOV
ETER3
ETERNIT ON
BOV
TPIS3
TRIUNFO PART ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados